Literature DB >> 18294266

Trans-sacral (Kraske) approach for gastrointestinal stromal tumour of the lower rectum: old procedure for a new disease.

P Gervaz1, O Huber, P Bucher, P Sappino, P Morel.   

Abstract

Gastrointestinal stromal tumours (GISTs) of the lower rectum are rare cancers from mesenchymatous origin, which are characterized by; 1) the absence of metastases in loco-regional lymph nodes; and 2) a tendency to grow opposite to the intestinal lumen. Thus, the two preferred surgical approaches for rectal adenocarcinomas (i.e. abdominal and transanal) are inappropriate for GISTs, due to: 1) the uselessness of total mesorectal excision; and 2) to the difficulty to locate the tumour with a transanal approach. We report here a case of a large GIST of the lower rectum which was successfully treated with a posterior trans-sacral approach. Lower rectum GISTs are good indications for the Kraske procedure, and this relatively new disease entity may contribute to the reintroduction of an old procedure into the armamentarium of 21(st) century colorectal surgeons.

Entities:  

Mesh:

Year:  2008        PMID: 18294266     DOI: 10.1111/j.1463-1318.2008.01489.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  11 in total

1.  The Kraske procedure: no more indications for benign lesions?

Authors:  A Ghellal; B Trilling; J-L Faucheron
Journal:  Tech Coloproctol       Date:  2019-06-26       Impact factor: 3.781

2.  Colorectal gastrointestinal stromal tumor.

Authors:  A Amato
Journal:  Tech Coloproctol       Date:  2010-11       Impact factor: 3.781

3.  Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib-an Indian series.

Authors:  Vishwas D Pai; Jean L Demenezes; Prachi S Patil; Avanish P Saklani
Journal:  J Gastrointest Oncol       Date:  2016-04

4.  Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors.

Authors:  D Centonze; E Pulvirenti; A Pulvirenti D'Urso; S Franco; N Cinardi; G Giannone
Journal:  Tech Coloproctol       Date:  2013-01-30       Impact factor: 3.781

5.  Management of a case of high-risk gastrointestinal stromal tumor in rectum by transanal minimal invasive surgery.

Authors:  Pramod Nepal; Shinichiro Mori; Yoshiaki Kita; Kan Tanabe; Kenji Baba; Yasuto Uchikado; Hiroshi Kurahara; Takaaki Arigami; Masahiko Sakoda; Kosei Maemura; Shoji Natsugoe
Journal:  World J Surg Oncol       Date:  2018-08-11       Impact factor: 2.754

6.  Transsacrococcygeal approach in rectal gastrointestinal stromal tumour resection: 10-year experience at a single centre.

Authors:  Xiusen Qin; Chuangkun Li; Zifeng Yang; Wentai Guo; Huili Guo; Chun Chen; Rongkang Huang; Di Zhang; Huaiming Wang; Hui Wang
Journal:  Ann Transl Med       Date:  2021-02

7.  Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.

Authors:  Thanh-Khoa Huynh; Pierre Meeus; Philippe Cassier; Olivier Bouché; Sophie Lardière-Deguelte; Antoine Adenis; Thierry André; Julien Mancini; Olivier Collard; Michael Montemurro; Emmanuelle Bompas; Maria Rios; Nicolas Isambert; Didier Cupissol; Jean-Yves Blay; Florence Duffaud
Journal:  BMC Cancer       Date:  2014-03-05       Impact factor: 4.430

8.  Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: A report of two cases.

Authors:  Li-Feng Sun; Jin-Jie He; Shao-Jun Yu; Jing-Hong Xu; Jian-Wei Wang; Jun Li; Yong-Mao Song; Ke-Feng Ding; Shu Zheng
Journal:  Oncol Lett       Date:  2014-08-01       Impact factor: 2.967

Review 9.  Radiotherapy for Gastrointestinal Stromal Tumors.

Authors:  Emine Elif Ozkan
Journal:  Chin Med J (Engl)       Date:  2018-01-20       Impact factor: 2.628

Review 10.  Transvaginal excision of rectal stromal tumors: case reports and a literature review.

Authors:  Wang Shizhuo; Ni Sha; Chen Xueting; Wang He; Luan Nannan; Ma Xiaoxin
Journal:  World J Surg Oncol       Date:  2019-10-06       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.